Show simple item record

AuthorBasha, Ahmad
AuthorIbrahim, Mohamed Izham Mohamed
AuthorHamad, Anas
AuthorChandra, Prem
AuthorOmar, Nabil E.
AuthorAbdullah, Mohamed Abdul Jaber
AuthorAldapt, Mahmood B.
AuthorHussein, Radwa M.
AuthorMahfouz, Ahmed
AuthorAdel, Ahmad A.
AuthorShwaylia, Hawraa M.
AuthorEkeibed, Yaslem
AuthorAbuMousa, Rami
AuthorYassin, Mohamed A.
Available date2023-09-20T08:47:10Z
Publication Date2021
Publication NamePLoS ONE
ResourceScopus
ISSN19326203
URIhttp://dx.doi.org/10.1371/journal.pone.0255104
URIhttp://hdl.handle.net/10576/47789
AbstractBackground Iron deficiency anaemia (IDA) is a major health issues and common type of nutritional deficiency worldwide. For IDA treatment, intravenous (IV) iron is a useful therapy. Objective To determine the efficacy and cost-effectiveness (CE) of intravenous (IV) Ferric Carboxymaltose (FCM) versus IV Iron Sucrose (IS) in treating IDA. Data sources Electronic medical record i.e. Cerner system. Target population Adults patients with iron deficiency anaemia. Time horizon A 12-month period (01/01/2018-31/12/2018). Perspective Hamad Medical Corporation (HMC, a public hospital). Intervention IV Ferric Carboxymaltose versus IV Iron Sucrose. Outcome measures With regard to responses to treatment i.e., efficacy of treatment with FCM & IS in IDA patients, hemoglobin (Hgb), ferritin, and transferrin saturation (TSAT) levels were the primary outcomes. Additionally, the researchers also collected levels of iron, platelet, white blood cell (WBC), red blood cell (RBC), mean corpuscular hemoglobin (MCH), and mean corpuscular volume (MCV). The costs i.e. resources consumed (obtained from NCCCR-HMC) and the CE of FCM versus IS were the secondary outcomes. Results of base-case analysis There was a significant improvement in Hgb, RBC and MCH levels in the IS group than the FCM group. The overall cost of IS therapy was significantly higher than FCM. The medication cost for FCM was approximately 6.5 times higher than IS, nonetheless, it is cheaper in terms of bed cost and nursing cost. The cost effectiveness (CE) ratio illustrated that FCM and IS were significantly different in terms of Hgb, ferritin and MCH levels. Further, Incremental Cost Effectiveness Ratio (ICER) indicated that further justifications and decisions need to be made for FCM when using Hgb, iron, TSAT, MCH and MCV levels as surrogate outcomes. Results of sensitivity analysis Not applicable. Limitations The study did not consider the clinical or humanistic outcome. Conclusions The higher cost of FCM versus IS can be offset by savings in healthcare personnel time and bed space. ICER indicated that further justifications and decisions need to be made for FCM when using Hgb, iron, TSAT, MCH and MCV levels as surrogate outcomes.
Languageen
PublisherPublic Library of Science
Subjectferric carboxymaltose
ferritin
hemoglobin
iron
iron saccharate
transferrin
ferric carboxymaltose
ferric ion
iron saccharate
maltose
TitleEfficacy and cost effectiveness of intravenous ferric carboxymaltose versus iron sucrose in adult patients with iron deficiency anaemia
TypeArticle
Issue Number8-Aug
Volume Number16
dc.accessType Open Access


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record